Next-Gen Biotech Innovation — PREMS AI Biomedical Breakthrough
PREMS AI BIOMEDICAL has developed an FDA-cleared, AI-enhanced neuromuscular stimulation platform that empowers patients to self-administer rehabilitation therapy — restoring movement through intelligent, personalized stimulation powered by NVIDIA Jetson Nano AI processing.
Download Investor Documents

The PREMS AI System combines FDA-cleared neuromuscular stimulation with cutting-edge artificial intelligence to deliver adaptive, home-based rehabilitation that evolves with the patient.
Flexible, comfortable wearables for arms, legs, and hands
Stimulation responds to user's own muscle signals (FDA-cleared 1988)
NVIDIA Jetson Nano extracts signals from background noise in real-time
Wireless control, progress tracking, telehealth support
Designed for daily activities, not just clinical sessions

User attempts movement → Weak EMG signal detected
AI processes signal → Removes stimulation artifacts
System responds → Proportional electrical stimulation applied
Movement achieved → Neural pathways strengthened

Our Pitch Deck is available for immediate download. The Business Plan and Investor Summary are provided under a signed NDA — contact us to request access.
Full investor presentation covering the PREMS AI technology, market opportunity, and go-to-market strategy.
PDF · 3.2 MBComprehensive business plan including financial projections, operational roadmap, and competitive analysis.
This document is available to qualified investors and partners under a signed Non-Disclosure Agreement.
Executive summary for investors — key highlights, funding ask, and projected returns at a glance.
This document is available to qualified investors and partners under a signed Non-Disclosure Agreement.
Contact our team to discuss partnership opportunities, investment, or clinical integration of the PREMS AI platform.
Get in Touch